Regeneron Phase 3 Fianlimab Combination Misses Primary PFS Endpoint in First-Line Metastatic Melanoma

Regeneron's LAG-3 inhibitor program faces a recalibration after the Phase 3 trial of fianlimab plus cemiplimab failed to reach statistical significance on its primary endpoint of progression-free survival (PFS) improvement versus pembrolizumab monotherapy in first-line unresectable or metastatic melanoma. The result carries direct implications for biologics manufacturing commitments and CMO/CDO capacity allocations tied to this asset.

The 1,546-patient, randomized, double-blind trial evaluated two dose levels of the fianlimab-cemiplimab combination against pembrolizumab. The high-dose arm (1600 mg fianlimab / 350 mg cemiplimab every three weeks, n=508) recorded a median PFS of 11.5 months versus 6.4 months for pembrolizumab monotherapy, a numeric improvement of 5.1 months, but the hazard ratio of 0.845 (95% CI: 0.709–1.008) yielded a p-value of 0.0627, short of the threshold for statistical significance. The low-dose arm (400 mg fianlimab / 350 mg cemiplimab, n=422) showed a hazard ratio of 0.931 with p=0.4661. No new safety signals were identified across either combination arm.

For QA directors and regulatory affairs leads, the absence of new safety signals preserves optionality, but the failed primary endpoint means no near-term BLA or regulatory submission pathway for this indication. Manufacturing scale commitments for the fianlimab-cemiplimab combination in this line of therapy will require reassessment against the remaining clinical programme. Detailed results are expected at an upcoming medical meeting, which will provide the data package that process development and supply-chain teams need to model forward demand scenarios.

The programme is not closed. A separate Phase 3 head-to-head trial comparing the high-dose fianlimab combination against Opdualag (nivolumab and relatlimab-rmbw) in the same first-line metastatic melanoma population remains ongoing. That trial's outcome will be the next decision node for capacity planning across Regeneron's biologics network and any contracted external manufacturing partners supporting the cemiplimab and fianlimab supply chains.

CMO and CDO partners currently holding capacity reservations for this programme should monitor the forthcoming medical meeting data presentation, as the hazard ratio and confidence interval data will inform whether dose-level adjustments or indication pivots alter batch demand projections for either biologic.

Source: Regeneron Pharmaceuticals, Inc. via GlobeNewswire, May 15, 2026.